Market Overview
Size, mix, and treated population
- Brevintel analysis estimates the market at USD 2.7 billion in 2025 ($2.7B), rising to USD 5.4 billion ($5.4B) by 2035 at a 7.8% CAGR from 2026 to 2035.
- The detailed series moves from USD 2,531.68 million in 2025 to USD 5,350.88 million in 2035 within that 7.8% global CAGR outlook.
- A parallel size reading lists USD 2.5 billion in 2025 and USD 2.7 billion in 2026 alongside the USD 2.7 billion 2025 headline.
- Demand spans pharmacotherapy, surgery, and procedural interventions for trigeminal neuralgia (TN), postherpetic neuralgia (PHN), occipital neuralgia, and related neuropathic pain.
- Johnson & Johnson led with over 16% market share in 2025; Astellas, Biogen, Eli Lilly, Johnson & Johnson, and Medtronic collectively held 39%.
- A 2025 synthesis of 17 population-based studies reported pooled TN incidence of 25.33 per 100,000 person-years and annual prevalence of 45.38 per 100,000.
- In the United States, 10-18% of people with herpes zoster develop PHN, while roughly one in three Americans is expected to develop shingles during their lifetime.
- Revenue mixes high-volume, price-pressured generic medicines with lower-volume, higher-value surgical and interventional care.
Recognition versus incidence
- Brevintel analysis finds the path from USD 2,531.68 million in 2025 to USD 5,350.88 million in 2035 depends more on converting recognized, persistent pain into sustained treatment than on an assumed jump in incidence.
- Primary review of the 17 population-based studies synthesized by Jeong YD et al. identifies a substantially higher post-neuroimaging TN incidence measure than pre-imaging estimates, with a pronounced female burden.
- Diagnostic technology expands the pool that can be clinically classified and referred, rather than proving that the underlying disorder is rising at the same rate.
- PHN broadens the opportunity beyond TN, but shingles vaccination coverage and prevention efforts may reduce future PHN exposure even as aging and incomplete protection sustain near-term demand.
- Suppliers positioned across medication, diagnostic referral pathways, and escalation procedures are better placed than single-modality participants to capture this uneven conversion of prevalence into revenue.
- The estimates are directional forecast contributions and are not additive; they interact with reimbursement, generic substitution, and access constraints within the 7.8% global CAGR outlook.
Market Dynamics
Clinical and demographic drivers
- Neurological disease burden and population aging underpin chronic neuralgia management: nervous system disorders affected 180.3 million people in the United States in 2021, while diabetic neuropathy affected 17.1 million people.
- A U.S. cohort study found that PHN incidence increased over 1994-2018, with 12.8% of herpes zoster patients developing the condition.
- High-resolution imaging helps clinicians identify neurovascular compression in TN and distinguish patients who may benefit from decompression or ablative intervention.
- Successful selection can shift treatment from repeated drug trials to a procedural pathway with materially higher revenue per episode.
- Herpes zoster incidence rose in several Asia Pacific markets, including South Korea, where incidence increased from 4.23 to 9.22 per 1,000 person-years between 2006 and 2015.
- Japanese treatment patterns changed after pregabalin approval, with identified PHN patients rising from 107 to 505 in the cited study period.
- The combination of recognized disease, medicine availability, and expanding specialist capacity supports regional demand, although access remains uneven.
- Long-term drug treatment remains the largest route for many patients, while MRI-supported identification of neurovascular compression can move selected TN patients toward microvascular decompression (MVD), stereotactic radiosurgery, or percutaneous procedures.
Diagnosis, reimbursement, and access constraints
- A multicenter European TN survey found that 42.1% of patients were misdiagnosed at their first consultation, only 17.6% received a correct initial diagnosis, and the mean time to correct diagnosis was 7.2 months.
- Misclassification can delay specialist referral, prolong ineffective treatment, and lead to unnecessary dental interventions before a neuralgia pathway is considered.
- As of March 2026, proposed Medicare Local Coverage Determinations from a majority of Medicare Administrative Contractors would narrow chronic-pain peripheral nerve block coverage to a limited set of indications.
- The proposed framework retains radiofrequency neurolysis for TN but creates uncertainty for procedures used in conditions such as occipital neuralgia.
- Generic medicines improve affordability and sustain volume, yet they compress manufacturer revenue per treated patient.
- Advanced surgery, radiosurgery, and neuromodulation require specialist expertise, imaging capability, and reimbursement support, particularly in lower-income geographies.
- Brevintel analysis indicates that diagnostic friction and reimbursement tightening are more commercially significant than a simple cost-barrier narrative.
- Products and service models linked to defensible diagnosis, documented medical necessity, and durable outcomes are likely to be more resilient than those dependent on broad office-procedure reimbursement.
Segmentation Analysis
Treatment type
- Surgical procedures are forecast to grow at a 7.6% CAGR and exceed USD 3.5 billion by 2035, reflecting the economic weight of MVD, stereotactic radiosurgery, and percutaneous interventions.
- In Medicare claims analysis, approximately 6% of TN patients received surgery; MVD represented 51.1% of surgical cases and had an average cost of USD 40,434.95, compared with USD 38,062 for stereotactic radiosurgery.
- The limited share of patients receiving surgery leaves a substantial medically managed population, so procedural growth depends on referral, imaging, candidacy, and reimbursement rather than prevalence alone.
- Medications generated USD 826.8 million in 2025 and are projected to reach USD 1.8 billion by 2035.
- Carbamazepine remains central to TN because Tegretol is specifically labeled by the FDA for pain associated with true TN in 2025 prescribing information.
- Adverse-event risks, including hyponatremia, aplastic anemia, agranulocytosis, and severe dermatologic reactions, can limit dose escalation and long-term persistence.
- In PHN and broader neuropathic pain, gabapentinoids, tricyclic antidepressants, and duloxetine maintain a larger role, although generic competition reduces pricing power.
- A five-year Danish cohort found that 59% of MVD patients were pain-free without medication, compared with 19% of medically managed patients.
- At five years, 23% of MVD patients remained on active medication, versus 62% in the medical cohort, supporting surgical escalation for selected patients without making surgery a substitute across all TN.
Application
- TN is forecast to expand at an 8.0% CAGR and exceed USD 2.3 billion by 2035, supported by a defined pathway from carbamazepine-based therapy to imaging-supported evaluation for surgical options.
- Commercial value is amplified by the higher revenue intensity of intervention among carefully selected refractory TN patients.
- PHN represented USD 755.5 million in 2025 and is expected to reach USD 1.7 billion by 2035 at an 8.3% CAGR.
- PHN growth reflects herpes zoster exposure in older populations and persistent demand for symptom control after acute infection.
- The PHN segment is more medication-intensive than TN, creating opportunity for drug suppliers but exposing revenue to generic substitution and formulary management.
- Occipital neuralgia generated USD 465.8 million in 2025 and is projected to reach USD 957.8 million by 2035.
- A study of 44 patients receiving occipital nerve blocks reported satisfactory results lasting at least six months in 95.45% of participants.
- Reimbursement uncertainty for chronic peripheral nerve blocks may limit the translation of clinical utility into broad procedural revenue for occipital neuralgia.
End use
- Hospitals accounted for 42.6% of market revenue in 2025, reflecting their ability to combine advanced imaging, specialist consultation, medication management, surgical intervention, and complication care.
- Hospital settings are particularly important for TN patients progressing toward MVD or radiosurgery.
- Clinics are projected to increase from USD 653.4 million in 2025 to USD 1.4 billion by 2035, at an 8.2% CAGR.
- Clinic growth is supported by follow-up care, medication adjustment, and selected interventional pain management, although payer coverage will determine how much procedure volume can remain office-based.
- Ambulatory surgical centers are expected to grow from USD 494.2 million in 2025 to USD 1.0 billion by 2035, at a 7.7% CAGR.
- ASC roles are most relevant to percutaneous and lower-acuity procedures that can migrate from hospitals when patient selection, recovery requirements, and reimbursement permit.
- Medication remains structurally indispensable because it serves patients before diagnosis is resolved, those who are unsuitable for surgery, and PHN patients whose disease pathway differs from TN.
- Providers that can move eligible refractory patients efficiently from medical therapy to imaging and intervention may capture the highest-value care episodes, while pharmaceutical demand remains broader but more exposed to price erosion.
Regional Outlook
North America and Europe
- North America accounted for USD 1,144.37 million in 2025, or 45.2% of global revenue, and is projected to reach USD 2,307.94 million by 2035 at a 7.3% CAGR.
- Regional weight reflects reimbursement coverage, established neurosurgical capacity, premium drug pricing, and relatively high utilization of MVD and stereotactic radiosurgery.
- The United States reached USD 1.1 billion in 2025, following USD 847.5 million in 2022, USD 929.5 million in 2023, and USD 1.0 billion in 2024.
- Proposed Medicare restrictions on chronic peripheral nerve block coverage could affect outpatient procedural treatment, especially where indications do not fall within limited covered exceptions.
- North American growth should remain strongest in pathways with well-defined diagnosis, coding, and medical-necessity support.
- Europe generated USD 779.3 million in 2025.
- Europe benefits from established neurological and pain-care infrastructure, but treatment conversion can be slowed by referral and diagnostic failures, including first-contact misdiagnosis and unnecessary dental procedures.
- The commercial opportunity in Europe lies in reducing the interval between symptom presentation and confirmed diagnosis, particularly where specialist imaging and surgery are available.
Asia Pacific, Latin America, and Middle East & Africa
- Asia Pacific is forecast to record the highest regional CAGR, at 9.3% from 2026 to 2035.
- Demand is supported by aging populations, growing herpes zoster burden, and rising use of neuropathic-pain medicines, including expanding pregabalin and gabapentin expenditure for PHN in China.
- National database evidence in Japan recorded PHN incidence of 1.00 per 1,000 person-years, with risk rising sharply after age 60 and patients with PHN having a median age of 76 years.
- Specialized multidisciplinary pain management was available at only 38 designated university-hospital centers, despite chronic pain affecting an estimated 22.5% of Japan's adult population.
- This gap favors scalable pharmacotherapy and referral networks while limiting immediate procedural conversion, as noted in March 31, 2023 policy recommendations for chronic pain in Japan.
- Brevintel analysis expects Asia Pacific's 9.3% CAGR to outpace North America's 7.3% growth because expansion begins from a less fully treated patient base rather than from higher procedure prices alone.
- Latin America represented USD 122.0 million in 2025, with growth tied to improving chronic-pain recognition but constrained by affordability, uneven reimbursement, and limited access to advanced neurosurgical or neuromodulation care.
- Middle East & Africa generated USD 61.5 million in 2025, the smallest current revenue base, reflecting variable access to specialists, advanced imaging, and interventional pain services.
- Private-provider investment and hospital infrastructure can improve availability in selected Middle East & Africa markets, but the near-term trajectory remains dependent on financially accessible pathways outside major urban centers.
- Regional strategy should differentiate between markets where clinical demand is expanding and markets where the system can actually convert that demand into specialist treatment.
Competitive Landscape
Structure
- The top five market participants collectively account for approximately 39% of global revenue, indicating capabilities distributed across pharmaceutical, medical-device, imaging, and procedural-care competitors.
- Johnson & Johnson led with over 16% market share in 2025.
- Drug suppliers compete on formulary access, safety, dosing convenience, and persistence in chronic therapy.
- Device and procedure-oriented participants depend more heavily on specialist adoption, evidence of durable relief, and reimbursement.
- Imaging capability has indirect but important market relevance because improved identification of neurovascular compression can influence which patients progress from medication to surgery.
- In November 2023, Pacira BioSciences received FDA approval for a supplemental new drug application expanding the Exparel label to include administration in adults as an adductor canal block and as a sciatic nerve block in the popliteal fossa.
Pharmaceutical leaders
- Johnson & Johnson
- Eli Lilly
- Biogen
- Astellas
Device and interventional
- Medtronic